Table 3. Clinical characteristics of PML patients with seizures.

Patient No.	HCS	IRIS	peri-IRIS seizures (35 days)	HIV	PML-S/P	continued AED requirement
1	+	+	+	+	S	-
2	+	+	+	-*	P	na
3	+	+	+	-†	P	na
4	+	+	+	-‡	S	U
5	+	+	+	-‡	S	+
6	+	+	+	+	S	+
7	+	+	+	-*	P	na
8	+	+	-	+	S	+
9	+	+	-	+	S	+
10	+	+	-	+	S	+
11	+	+	-	+	S	+
12	+	-	na	-§	S	+
13	+	-	na	-¶	P	na
14	+	-	na	+	S	+
15	+	-	na	-¶	S	U
16	-	+	+	+	S	+
17	-	-	na	-**	P	na

Abbreviations: AED= anti-epileptic drug; HCS= hyperintense cortical T1-signal; HIV= human immunodeficiency virus; IRIS= immune reconstitution inflammatory syndrome; na= not applicable; PML= progressive multifocal leukoencephalopathy progressor; PML-P= PML-progressor; PML-S= PML-survivor; U= unknown/lost to follow up

^*Chronic Lymphocytic Leukemia treated with rituximab

^†Chronic Lymphocytic Leukemia treated with regimen that did not include rituximab

^‡Multiple sclerosis treated with natalizumab

^§Non-Hodgkins Lymphoma treated with rituximab

^¶lymphomatoid granulomatosis treated with rituximab

^¶CD4 lymphopenia

^**Common variable immunodeficiency